New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:00 EDTRNDY, PCYC, GILD, BIIB, ACPW, KING, RNG, IRT, CIG, ASBC, COMM, TCB, REGN, ICLR, CELG, AMGN, USPHOn The Fly: Analyst Initiation Summary
Active Power (ACPW) initiated with a Buy at Roth Capital... Amgen (AMGN) initiated with an Overweight at Morgan Stanley... Associated Banc-Corp (ASBC) initiated with a Neutral at DA Davidson... Biogen (BIIB) initiated with an Overweight at Morgan Stanley... Celgene (CELG) initiated with an Equal Weight at Morgan Stanley... Cemig (CIG) initiated with a Buy at Goldman... Gilead (GILD) initiated with an Equal Weight at Morgan Stanley... ICON plc (ICLR) initiated with an Outperform at Credit Suisse... Independence Realty Trust (IRT) initiated with a Buy at Deutsche Bank... Pharmacyclics (PCYC) initiated with an Equal Weight at Morgan Stanley... Regeneron (REGN) initiated with an Equal Weight at Morgan Stanley... RingCentral (RNG) initiated with an Outperform at Macquarie... Roundy's (RNDY) initiated with a Buy at BofA/Merrill... TCF Financial (TCB) initiated with a Neutral at DA Davidson... King Digital (KING) initiated with a Neutral at Sterne Ageel... U.S. Physical Therapy (USPH) initiated with an Overweight at Stephensl... CommScope (COMM) initiated with a Buy at Longbow.
News For ACPW;AMGN;ASBC;BIIB;CELG;CIG;GILD;ICLR;IRT;PCYC;REGN;RNG;RNDY;TCB;KING;USPH;COMM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 11, 2014
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
10:39 EDTKINGOptions with decreasing implied volatility
Subscribe for More Information
10:14 EDTREGNRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
10:00 EDTRNGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
06:11 EDTRNGRingCentral initiated with an Outperform at Macquarie
Target $16.
05:26 EDTREGNRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
15:54 EDTAMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
10:17 EDTKINGOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:20 EDTGILDOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTGILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
08:22 EDTCOMMNetwork equipment makers slip after AT&T projects lower 2015 capital spending
Subscribe for More Information
08:12 EDTCOMMAT&T 2015 capex reduction negative for select stocks, says JPMorgan
Subscribe for More Information
07:20 EDTGILDGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:19 EDTCELG, REGNCredit Suisse to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use